IMMUCELL CORP
ICCCNASDAQTrading Snapshot
- Day Range
- $575.62 – $592.58
- 52-Week Range
- $4.52 – $12.10
- Volume
- $3.62B
- Avg Volume
- $3.66B
- Shares Outstanding
- 9.1M
- Next Earnings
- Sep 19, 2026
Fundamentals Snapshot
- Annual Revenue
- $28M
- Last Q Revenue
- $10M
- P/E Ratio
- —
- P/S Ratio
- 3.3x
- EPS (TTM)
- $-0.06
- Dividend Yield
- —
Why Investors Own ICCC
- ✓High-growth profile — revenue up -9.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 26% gross margin and 14% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About IMMUCELL CORP
ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market and international regions. Among its key products is First Defense, an orally administered preventative designed to combat scours in newborn dairy and beef calves. The company also provides Tri-Shield First Defense, a passive antibody treatment effective against E. coli, coronavirus, and rotavirus. Additionally, ImmuCell offers the California Mastitis Test, a diagnostic instrument used to quantify somatic cell counts in milk and identify which specific udder quarter may be affected by mastitis. Its Dual-Force First Defense product, incorporating a whey protein concentrate, caters to the nutritional and animal feed supplement industries. Currently under development is Re-Tain, a Nisin-based intramammary therapy targeting subclinical mastitis in lactating dairy cows. The company primarily distributes its products through a network of animal health distributors. ImmuCell Corporation was established in 1982 and is based in Portland, Maine.
